Helix BioPharma's product development initiatives include its novel L-DOS47 new drug product candidate for the treatment of inoperable, locally, advanced, recurrent, or metastatic non-small cell lung cancer and pancreatic cancer. For more information contact Investor Relation or Shareholder Services.